Key takeaways
- Tesamorelin is a single GHRH analogue that acts only on the GHRH receptor.
- CJC-1295 + Ipamorelin combines a GHRH analogue with a ghrelin-receptor agonist, stimulating GH through two pathways.
- Tesamorelin has a much larger clinical record, including an approved indication. The blend's evidence is mostly from studies of each component separately.
In this guide
Browse performance research →At a glance
| CJC-1295 + Ipamorelin | Tesamorelin | |
|---|---|---|
| Format | Blend: 5mg + 5mg in one vial | Single compound, 10mg |
| Receptors | GHRH receptor + ghrelin receptor (GHS-R1a) | GHRH receptor only |
| GHRH analogue design | Mod GRF 1-29: first 29 amino acids, four substitutions | Full 44 amino acids, N-terminal trans-3-hexenoyl group |
| Duration | Short acting (no DAC) | Stabilized, longer than native GHRH |
| Clinical evidence | Limited; mostly studies of each component | Randomized trials; approved in 2010 as Egrifta for one indication |
| Main research focus | Combined GHRH and ghrelin signalling, GH pulsatility | GH/IGF-1 axis, visceral and liver fat |
One pathway vs two
Growth hormone release from the pituitary is driven by two stimulating signals: GHRH and ghrelin, with somatostatin acting as the brake. (Our guide to GH signalling covers this system in detail.)
Tesamorelin activates only the GHRH pathway. CJC-1295 + Ipamorelin activates both: CJC-1295 (no DAC) on the GHRH receptor, and ipamorelin on the ghrelin receptor. Research on the GH axis has shown that activating both pathways together produces a stronger GH response than either alone, which is the reasoning behind the blend.
Two different GHRH analogues
Even the GHRH components differ. Tesamorelin keeps the full 44-amino-acid sequence of human GHRH and adds a trans-3-hexenoyl group for stability. CJC-1295 without DAC (Mod GRF 1-29) uses only the first 29 amino acids, the minimum needed for full activity, with four substitutions that resist breakdown.
The evidence behind each
This is the biggest practical difference. Tesamorelin has been through randomized, placebo-controlled trials, most notably on visceral fat in HIV-associated abdominal fat accumulation (Falutz et al., 2007, 2010), and it was approved in 2010 as Egrifta for that specific indication.
For CJC-1295 + Ipamorelin, published research mostly covers each compound on its own: ipamorelin's selectivity in animal studies (Raun et al., 1998), and clinical pharmacology of the long-acting CJC-1295 with DAC (Teichman et al., 2006), which doesn't transfer directly to the no-DAC form. Published studies of the combination itself are limited.
Which suits which research question?
- Tesamorelin suits research on the GHRH pathway alone, the GH/IGF-1 axis, and body-composition questions where there's an existing clinical literature to compare against.
- CJC-1295 + Ipamorelin suits research on how GHRH and ghrelin-receptor signalling interact, and on pulsatile GH release patterns.
- Both together: some researchers use tesamorelin as a single-pathway comparison for two-pathway experiments.
Neither is an approved product for research-grade use. CJC-1295 and ipamorelin are named among unauthorized peptides in Health Canada's 2026 advisory.
Frequently asked questions
What is the difference between CJC-1295 + Ipamorelin and tesamorelin?
Tesamorelin is a single GHRH analogue acting only on the GHRH receptor. CJC-1295 + Ipamorelin pairs a GHRH analogue with a ghrelin-receptor agonist, stimulating growth hormone through two pathways.
Which has more clinical research?
Tesamorelin. It has been studied in randomized controlled trials and was approved in 2010 as Egrifta for a specific indication. Research on CJC-1295 + Ipamorelin mostly covers each compound separately.
Are tesamorelin and CJC-1295 the same type of peptide?
Both are GHRH analogues, but they're built differently. Tesamorelin keeps all 44 amino acids of GHRH; CJC-1295 (no DAC) uses the first 29 with four substitutions.
Does ipamorelin act like GHRH?
No. Ipamorelin acts on the ghrelin receptor (GHS-R1a), a separate pathway that also stimulates growth hormone release.
References
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
